The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

The stock's rise snapped a three-day losing streak.

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

Hello, and welcome to the Kenvue First Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

(Reuters) -Kenvue beat quarterly profit and revenue estimates on Thursday as better-than-expected demand for cough-and-cold ...

May 8 (Reuters) - Kenvue (KVUE.N), opens new tab on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a $150 million impact from ...